Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05491330
Other study ID # GRC/1/22/1038
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 21, 2022
Est. completion date October 27, 2022

Study information

Verified date January 2023
Source Genuine Research Center, Egypt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)


Description:

Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the 90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for untransformed data of Ke, tmax and t1/2e. The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax, AUC0→t and AUC0→∞ to be within 80.00-125.00%. A comprehensive final report will be issued upon the completion of the study.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 27, 2022
Est. primary completion date September 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy male or female, age 18 to 55 years, inclusive. 2. Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI). 3. Medical demographics without evidence of clinically significant deviation from normal medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous system, or metabolic abnormalities. 4. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator. 5. Females should be on a suitable birth control method. 6. Fully informed subjects that consented to participate in the study. Exclusion Criteria: 1. Subjects with known allergy to the products tested. 2. Female subjects who were pregnant or nursing. 3. Acute infection within one week preceding first study drug administration. 4. History of drug or alcohol abuse. 5. Subject does not comply with the stated instruction of not taking any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study. 6. Subject is on a special diet (for example subject is vegetarian). 7. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period. 8. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study. 9. Subject has a family history of severe diseases which have direct impact on the study. 10. Participation in a bioequivalence study or in a clinical study within the last 8 weeks before first study drug administration. 11. Subject intends to be hospitalized within 3 months after first study drug administration. 12. Subjects who have donated blood or lost more than 500 mL blood within 3 months prior to the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Nirmatrelvir 150 mg + Ritonavir 100 mg (test)
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg

Locations

Country Name City State
Egypt Genuine Research Center GRC Cairo

Sponsors (2)

Lead Sponsor Collaborator
Genuine Research Center, Egypt Eva Pharma

Country where clinical trial is conducted

Egypt, 

References & Publications (3)

Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353. Erratum In: J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):101. — View Citation

Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8. — View Citation

Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Maximal measured plasma concentration Up to 48 hours post dose in each treatment period
Secondary Time of the maximum plasma concentration (Tmax) The amount of time that a drug is present at the maximum concentration in serum Up to 48 hours post dose in each treatment period
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1